A Phase 4 interventional study of Baricitinib 4 MG and Placebo in Rheumatoid Arthritis, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Chinese University of Hong Kong · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 18th largest by planned enrollment, is one of 2 that started in 2023, is one of 9 in phase 4, and was the 21st registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
13 studies in Arthritis, Rheumatoid by Chinese University of Hong Kong: 1 open now, 2 under way, none of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 13 studies in Arthritis, Rheumatoid by Chinese University of Hong Kong, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 4, and was the 13th registered.
Chinese University of Hong Kong’s Arthritis, Rheumatoid studies by the year they started, since 2004.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chinese University of Hong Kong’s 13 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Objective To investigate the effect of Janus kinase (JAK) inhibition by baricitinib on erosion healing in rheumatoid arthritis (RA) patients with active disease using high-resolution peripheral quantitative computer tomography(HR-pQCT).
Hypothesis JAK inhibitor can lead to healing of existing erosion in RA patients with active disease.
Design and subjects This is a 24-week, randomized, placebo-controlled, double-blind study. We plan to enroll 60 adult patients with active RA (Disease activity score 28-C-reactive protein [DAS28-CRP]>3.2) and 1 bone erosion on HR-pQCT. They will be randomized 1:1 to receive JAK inhibitor (baricitinib 4mg once daily) or placebo for 24 weeks. Medications will be adjusted according to a standard protocol aiming to achieve low disease activity. Patients requiring biologic or other targeted synthetic disease-modifying-anti-rheumatic-drugs will be excluded.
Study instruments HR-pQCT of the 2-4 metacarpophalangeal(MCP) will be done at baseline and 24 weeks. Inflammatory cytokine profile and bone cartilage interface biomarkers will also be checked at baseline and 24 weeks. Clinical response will be monitored using DAS28-CRP.
Main outcome measures and analysis The primary outcome is the proportion of patients with erosion volume regression on HR-pQCT comparing the two groups by chisquare test.
Rheumatoid arthritis (RA) is a common chronic inflammatory arthritis affecting 0.35% of the population in Hong Kong. Uncontrolled arthritis can lead to joint destruction, functional disability and decreased quality of life. We also found that the disease carried substantial socioeconomic costs.
Bone erosions are specific to RA reflecting disease severity, and can be used to monitor disease progression. In early RA, functional capacity is most associated with disease activity, but in established disease, with joint damage. A recent study also showed joint tenderness, a crucial determinant of disease activity, was associated with structural damage rather than sonographic synovitis in non-swollen joints in established RA. In fact, prevention of erosion on radiographs is used to define the efficacy of disease modifying anti-rheumatic drugs (DMARDs) in RA. After all, the ultimate aims of management in RA are to reduce symptoms, preserve function and maintain quality of life.
The 60 patients with erosion will be randomized in a 1:1 ratio to JAK1 inhibitor (n=30) or placebo (n=30) group. Randomization will be performed using a computer-generated randomization list provided by the research pharmacist, using a permuted blocks design with block sizes of 4. Allocation concealment will be ensured by the use of sequentially numbered, opaque, sealed envelopes. Treatment will be masked to patients and investigators.
All the participants will be instructed to take one study capsule (4 mg baricitinib or placebo) daily for 24 weeks. They will be treated to the target of DAS28 remission or low disease activity (LDA) at PWH throughout the study period according to a standard protocol modified to our study based on the EULAR recommendation and the Hong Kong guideline on the use of DMARDs. Disease activity and adverse events will be monitored at 4 weeks, 12 weeks and 24 weeks. Patients will be advised to reach out to the rheumatologists earlier if the condition changes unexpectedly. Changes in treatment, e.g. the switching to a new csDMARD including leflunomide, hydroxychloroquine, or sulfasalazine or the dosage of csDMARDs and changes in the dosage or the addition of glucocorticoids or nonsteroidal anti-inflammatory drugs are allowed throughout the study. The use of b/tsDMARDs, bisphosphonates, denosumab, teriparatide or systemic glucocorticoid > prednisolone 10 mg/day equivalent will be prohibited throughout the study. Participants who required rescue b/tsDMARDs will be withdrawn from the study and excluded from the final analysis.
The following clinical variables will be assessed at each visit: erythrocyte sedimentation rate (ESR), CRP, number of swollen joints (0-28), number of tender joints (0-28), visual analogue scale (VAS) for pain (0-100 mm=most pain), VAS for patient's global assessment (0-100 mm=worst score), VAS for physician's global assessment (0-100 mm=worst score), and DAS28 score. The number of damaged joints will be assessed at baseline and the end of the study. Rheumatoid factor status and anti-cyclic citrullinated peptide antibodies status will be determined at baseline. Functional disability is assessed by the disability index of HAQ (0-3=most functional disability). ACR20/50/70 responses are defined as at least 20%, 50%, and 70% improvement in swollen joint and tender joint counts, and three of five other variables (i.e., ESR or CRP, HAQ score, pain score, and physicians' and patients' global assessments).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized into JAKi group will receive one capsule of baricitinib (4mg) daily for 24 weeks.
Drug: Baricitinib 4 MG
Patients randomized into placebo group will receive one capsule of placebo daily for 24 weeks.
Drug: Placebo
1 capsule (4mg) daily for 24 weeks
Also known as: Olumiant
1 capsule daily
The proportion of patients with reduction of erosion volume on HR-pQCT over 2-4 metacarpophalangeal (MCP 2-4) at 24 weeks comparing JAK inhibitor group and placebo group.
Bone erosion will be assessed at MCP 2-4 of the most affected hand or dominant hand when both hands are equally affected. The primary outcome measurement, the comparison of proportion of patients with erosion volume reduction in the 2 groups, will be analyzed by the Chi-square test. Clinical variables which are significantly different between the 2 groups in the univariate analyses and are biologically plausible (eg. age, sex, disease duration, disease activity or treatment) will be adjusted in the multivariate logistic regression model to confirm the JAK inhibitor treatment effect.
Time frame: 24 weeks
The proportion of patients with definitive erosion healing on HR-pQCT at 24 weeks comparing the 2 groups, with definite erosion defined as 1) a decrease in erosion volume exceeding the smallest
Bone erosion will be assessed at MCP 2-4 of the most affected hand or dominant hand when both hands are equally affected. The secondary outcome on definitive erosion healing will be compared likewise. To address the secondary outcomes on changes of erosion parameters, disease activity and biomarkers, the comparison will be done by T-test or Mann-Whitney U test. The within group changes of these measurements before and after treatment will be examined using paired t-test or Wilcoxon signed-rank test. Independent factors predicting treatment response in the JAK inhibitor group will be analyzed by multivariate logistic regression. A 2-tailed probability value of p\<0.05 is considered statistically significant.
Time frame: 24 weeks
Changes in dimensions of erosion (depth, width and volume), marginal osteosclerosis and joint space width (minimal, maximal, asymmetry and distribution) on HR-pQCT at 24 weeks comparing the 2 groups.
Bone erosion will be assessed at MCP 2-4 of the most affected hand or dominant hand when both hands are equally affected. The secondary outcome on definitive erosion healing will be compared likewise. To address the secondary outcomes on changes of erosion parameters, disease activity and biomarkers, the comparison will be done by T-test or Mann-Whitney U test. The within group changes of these measurements before and after treatment will be examined using paired t-test or Wilcoxon signed-rank test. Independent factors predicting treatment response in the JAK inhibitor group will be analyzed by multivariate logistic regression. A 2-tailed probability value of p\<0.05 is considered statistically significant.
Time frame: 24 weeks
Changes in RA disease activity at 24 weeks comparing the 2 groups.
Disease activity and adverse events will be monitored at 4 weeks, 12 weeks and 24 weeks. The following clinical variables will be assessed at each visit: erythrocyte sedimentation rate (ESR), CRP, number of swollen joints (0-28), number of tender joints (0-28), visual analogue scale (VAS) for pain (0-100 mm=most pain), VAS for patient's global assessment (0-100 mm=worst score), VAS for physician's global assessment (0-100 mm=worst score), and DAS28 score. The number of damaged joints will be assessed at baseline and the end of the study. Rheumatoid factor status and anti-cyclic citrullinated peptide antibodies status will be determined at baseline. Functional disability is assessed by the disability index of HAQ (0-3=most functional disability).
Time frame: 24 weeks
Changes in the inflammatory cytokines/chemokines and bone-cartilage biomarkers comparing the 2 groups.
Bone erosion will be assessed at MCP 2-4 of the most affected hand or dominant hand when both hands are equally affected. The secondary outcome on definitive erosion healing will be compared likewise. To address the secondary outcomes on changes of erosion parameters, disease activity and biomarkers, the comparison will be done by T-test or Mann-Whitney U test. The within group changes of these measurements before and after treatment will be examined using paired t-test or Wilcoxon signed-rank test. Independent factors predicting treatment response in the JAK inhibitor group will be analyzed by multivariate logistic regression. A 2-tailed probability value of p\<0.05 is considered statistically significant.
Time frame: 24 weeks
Predictors of response to JAK inhibitor treatment in terms of erosion healing.
The secondary outcome on definitive erosion healing will be compared likewise. To address the secondary outcomes on changes of erosion parameters, disease activity and biomarkers, the comparison will be done by T-test or Mann-Whitney U test. The within group changes of these measurements before and after treatment will be examined using paired t-test or Wilcoxon signed-rank test. Independent factors predicting treatment response in the JAK inhibitor group will be analyzed by multivariate logistic regression. A 2-tailed probability value of p\<0.05 is considered statistically significant.
Time frame: 24 week
Plan to share: Yes — Anonymized clinical data can be shared upon reasonable request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: After publication of the final manuscript
Access criteria: For research purpose
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Feb 2026, 26 months after the start.
Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 26 months is below that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib
Chinese University of Hong Kong →